1. EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
   Jiyoul Yang et al, 2018, Cancer Research and Treatment CrossRef
2. Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients
   Tao Jiang et al, 2017, Oncotarget CrossRef
3. Intra-pleural and intra-peritoneal tocilizumab therapy for managing malignant pleural effusions and ascites: The Regional Immuno-Oncology Trial (RIOT)−2 study protocol
   Hyun Park et al, 2024, Surgical Oncology Insight CrossRef
4. A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non‐small‐cell lung cancer
   Keke Nie et al, 2020, Thoracic Cancer CrossRef
5. Current status and future of anti-angiogenic drugs in lung cancer
   Xuan Yan et al, 2023, Clinical and Experimental Medicine CrossRef
6. Effect of malignant‐associated pleural effusion on endothelial viability, motility and angiogenesis in lung cancer
   Chih‐Ying Changchien et al, 2020, Cancer Science CrossRef
7. Comparing approaches to the management of malignant pleural effusions
   José M. Porcel et al, 2017, Expert Review of Respiratory Medicine CrossRef
8. ERS/EACTS statement on the management of malignant pleural effusions
   Anna C Bibby et al, 2019, European Journal of Cardio-Thoracic Surgery CrossRef
9. Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers
   Ralph Llewel Sabang et al, 2018, Expert Review of Respiratory Medicine CrossRef
10. When to add anti-angiogenesis drugs to EGFR-mutated metastatic non–small cell lung cancer patients: a real-world study from Taiwan
    Chieh-Lung Chen et al, 2022, BMC Cancer CrossRef
11. The Role of Hyperthermic Intrathoracic Chemotherapy (HITHOC) in Thoracic Tumors
    Federica Danuzzo et al, 2024, Cancers CrossRef
12. Failure pattern and radiotherapy exploration in malignant pleural effusion non-small cell lung cancer treated with targeted therapy
    Qingsong Li et al, 2023, Frontiers in Oncology CrossRef
13. Novel insights into the systemic treatment of lung cancer malignant pleural effusion
    Claire Tissot et al, 2019, The Clinical Respiratory Journal CrossRef
14. Malignant Pleural Effusion: Still a Long Way to Go
    Fausto Meriggi, 2019, Reviews on Recent Clinical Trials CrossRef
15. Local biomaterial-assisted antitumour immunotherapy for effusions in the pleural and peritoneal cavities caused by malignancies
    Yajie Sun et al, 2021, Biomaterials Science CrossRef
16. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
    Haruhiro Saito et al, 2019, The Lancet Oncology CrossRef
17. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma‐induced malignant pleural effusion
    Hong Tao et al, 2018, Thoracic Cancer CrossRef
18. ERS/EACTS statement on the management of malignant pleural effusions
    Anna C. Bibby et al, 2018, European Respiratory Journal CrossRef
19. Malignant pleural effusion as a predictor of the efficacy of anti‐PD‐1 antibody in patients with non‐small cell lung cancer
    Ryota Shibaki et al, 2019, Thoracic Cancer CrossRef
20. Development and validation of the CAIL prognostic score in non‐small cell lung cancer patients with malignant pleural effusion
    Tianyuan Li et al, 2023, The Clinical Respiratory Journal CrossRef
21. Making cold malignant pleural effusions hot: driving novel immunotherapies
    Pranav Murthy et al, 2019, OncoImmunology CrossRef
22. Liquid biopsy of circulating tumor DNA and biosensor applications
    Xuanying Li et al, 2019, Biosensors and Bioelectronics CrossRef
23. Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases
    D. Marquez-Medina et al, 2016, Clinical and Translational Oncology CrossRef
24. Evaluation of efficacy and safety for bevacizumab in treating malignant pleural effusions caused by lung cancer through intrapleural injection
    Sun Zongwen et al, 2017, Oncotarget CrossRef
25. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non‑small cell lung cancer (Review)
    Yao Chen et al, 2018, Molecular Medicine Reports CrossRef
26. Malignant Pleural Effusion from Lung Cancers with Driver Mutations
    Macy Mei-sze Lui et al, 2018, Current Pulmonology Reports CrossRef